All News

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Standard prediction models that assess an individual’s risk of developing dementia and how to prevent it are limited in their ability to do so, showing high error rates and a higher chance of receiving a false-positive result, according to a recent study.

The FDA approved a molecular test for emergency use and a supplemental new drug application for a blood sugar medication.

Immunocompromised status still appears to be one of the highest independent risk factors for pneumococcal pneumonia in middle-aged and older adults.

The novel antibiotic combines aztreonam, a monobactam β-lactam, with avibactam, a broad-spectrum β-lactamase inhibitor.

QR codes were invented almost 30 years ago and are used on everything from cereal boxes to repair manuals, yet pharmacy has yet to even consider them.

Multivitamins were associated with increased cellular oxygen consumption and more optimal blood nutrition biomarkers.

Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.

Current social determinants of health found to have a significant impact on sleep health.

How pharmacy teams can remove cost barriers to cardiac care.

Pharmacists can help patients live a life of meaning and gratitude after cancer recovery.

Best practices to safely, legally source prescription medications in Mexico.

Products treat ulcerative colitis, urinary tract infection, and psoriatic arthritis.

Liam Volk, MPharm, president-elect of the Pharmacists’ Defence Association LGBT+ Network, discussed how pharmacists can best support their LGBTQ+ colleagues and patients.

Family members should also be trained in how to administer seizure first aid, apply a tourniquet to control bleeding, operate an automated external defibrillator, and perform cardiopulmonary resuscitation.

The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.

The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.

Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).

With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.

Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.

Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.

VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.

Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.

Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.

A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.